MIRA INFORM REPORT

 

 

Report No. :

345957

Report Date :

05.11.2015

 

IDENTIFICATION DETAILS

 

Name :

MARPEL PHARMA SA

 

 

Registered Office :

3 Calle A 4-24 Z.10 Interior, Guatemala City

 

 

Country :

Guatemala

 

 

Date of Incorporation :

10.11.2009

 

 

Legal Form :

Sociedad Anonima

 

 

Line of Business :

Pharmaceutical products supplier

 

 

No. of Employees :

16

 

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Status :

Moderate

 

 

Payment Behaviour :

Slow but correct

 

 

Litigation :

Clear

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – March 31, 2015

 

Country Name

Previous Rating

(31.12.2014)

Current Rating

(31.03.2015)

Guatemala

B1

B1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

GUATEMALA - ECONOMIC OVERVIEW

 

Guatemala is the most populous country in Central America with a GDP per capita roughly one-half that of the average for Latin America and the Caribbean. The agricultural sector accounts for 13.7% of GDP and 32% of the labor force; key agricultural exports include sugar, coffee, bananas, and vegetables. The 1996 peace accords, which ended 36 years of civil war, removed a major obstacle to foreign investment, and since then Guatemala has pursued important reforms and macroeconomic stabilization. The Dominican Republic-Central America Free Trade Agreement (CAFTA-DR) entered into force in July 2006, spurring increased investment and diversification of exports, with the largest increases in ethanol and non-traditional agricultural exports. While CAFTA-DR has helped improve the investment climate, concerns over security, the lack of skilled workers, and poor infrastructure continue to hamper foreign direct investment. The distribution of income remains highly unequal with the richest 20% of the population accounting for more than 51% of Guatemala's overall consumption. More than half of the population is below the national poverty line, and 13% of the population lives in extreme poverty. Poverty among indigenous groups, which make up more than 40% of the population, averages 73%, with 22% of the indigenous population living in extreme poverty. Nearly one-half of Guatemala's children under age five are chronically malnourished, one of the highest malnutrition rates in the world. Guatemala is the top remittance recipient in Central America as a result of Guatemala's large expatriate community in the United States. These inflows are a primary source of foreign income, equivalent to one-half of the country's exports or one-tenth of its GDP. In November 2014 along with his counterparts from El Salvador and Honduras, President PEREZ MOLINA announced the “Plan of the Alliance for Prosperity in the Northern Triangle.” This plan seeks to address the challenges facing the three Northern Triangle countries, including steps the governments will take to stimulate economic growth, increase transparency and fiscal responsibility, reduce violence, modernize the justice system, improve infrastructure, and promote educational opportunities over the next several years.

 

Source : CIA

 

IDENTIFICATION

 

Ordered as:

MARPEL PHARMA SA

Address in the order:

3A CALLE A4-24 ZONA 10 INTERIOR A 01010 GUATEMALA CENTRO

Comments on data supplied:

The name provided is incomplete, please find in the report the legal name of the company.

Legal Name:

MARPELPHARMA GUATEMALA SA

Trade Name:

MARPEL PHARMA GUATEMALA

Legal Address

3 Calle A 4-24 Z.10 Interior

Postal Town

Guatemala City

Post Code

N.A.

Primary Geographic Area

Guatemala

Country

GT

Operative Address

3 Calle A 4-24 Z.10 Interior

Guatemala City, Guatemala

Telephone:

+502 2360 8484 / +502 2360 8483

NIT :

67680895

Fax:

+502 2360 8466

Legal Form:

Sociedad Anonima

Email:

m.ramazzini@marpelpharma.com / m.ramirez@marpelpharma.com

Registered in:

GT

Website:

http://marpelpharma.com/

Date Created:

2009

Manager:

Mateo Estuardo Menendez Ramazzini, General Manager

Date Incorporated:

November 10th, 2009

Staff:

16

Stock:

N.A.

 

 

Value:

N.A

Activity:

Pharmaceutical products supplier

 

 

DIRECTORS/MANAGEMENT

 

Management:

Mateo Estuardo Menendez Ramazzini, General Manager

Samuel Sosa, Sales Manager

Mario Ramirez, Finacial Manager

 

 

 

NEGATIVE INFORMATION

 

Legal Filings

 The sources consulted record no detrimental legal or labor court information.

 

Public

NO

 

 

SHARE & SHARE CAPITAL INFORMATION

 

Shareholders

Listed at the stock exchange:

 

NO

Shareholders Parent Company(ies):

This is a private company. The company is a subsidiary of Marpel Pharma SA of Costa Rica.

 

Edificio Multibodegas Bodega # 7 Del Cruce de Multiplaza Escazu

800 metros Noroeste

San Jose

Costa Rica

Tel.: (506) 2215-4215

Fax: (506) 2215-4214

 

 

PAYMENT INFORMATION

 

Payments

Slow but correct

 

 

GROUP STRUCTURE & AFFILIATED COMPANIES

 

RELATED COMPANIES:

 

Marpel Pharma SA has other subsidiaries in Honduras, Mexico, El Salvador and Argentina.

 

 

FINANCIAL INFORMATION

 

FINANCIALS - COMMERCIAL TRENDS AND FORECAST

As a private company the subject does not publish any financial statements.

We have contacted the company but could not reach anyone who could provide us any financial data.

However our financial sources could provide us with the following data.

Those figures are estimates provided by confidential banking and financial institutions working with the company.

 

Currency

DATE

USD

2011

Turnover

2 400 000

The cash flow is

Normal

Comments on the financial data: This information was not verified by the company.
It was not possible to obtain more recent financial data for this subject.

 

FINANCIAL SUMMARY

Profitability

N.A.

Indebtedness

CONTROLLED

Cash

Normal

FOREIGN EXCHANGE RATES

 

N/a

 

 

ADDITIONAL INFORMATION

 

GEOPOLITICS - GUATEMALA

POLITICAL DATA

ECONOMIC DATA

Form of Government: Republic

Economic Risk: Low

Currency: 1,00 USD = 7,66950 GTQ
Branch Situation:Stable

 

BANKS

Name of the Bank

Banco Promerica Guatemala

Location

v. Reforma 9-55 Z. 10 Edificio Reforma 10 2do nivel, Guatemala, CA 01010

Comments

This information was not verified by the company.

 

BUSINESS

HISTORY

 

The company was created and incorporated in Guatemala in 2009.

PRINCIPAL ACTIVITY

 

Distribution of pharmaceutical products

Products/Services description:

 

The company distributes three product lines:

Pharmaceuticals

Biomedical equipment

Veterinary products

Sales are:

 

Wholesale

Brands:

 

Sages products, Medicall Actions, Histo

Clients:

 

Professionals of industry such as:

Farmedical SRL (Mexico)

The company has experience working as a government supplier, having been awarded 624 contracts between 2010 and 2015 for a total of GTQ 13 944 792.64.

Suppliers:

 

It was not possible to obtain the name of any suppliers for this subject.

Operations area:

 

National, International

The company imports from Worldwide, depending on the need

The company exports to Mexico

Trade References:

 

It was not possible to obtain trade references for this subject.

The subject employs 16 employee(s)

Comments on staff:

 

This information was not verified by the company.

PAYMENTS

 

Slow but correct

LOCATION

Headquarters

 

3 Calle A 4-24 Z.10 Interior

Guatemala City, Guatemala

Comments on location:

 

This information was not verified by the company.

Branches:

 

We could not locate any company branches.

 

 

NOTES & COMMENTS

 

Final Opinion

This is a small Guatemalan company that has been in operations in the country since 2009.

The company distributes all kinds of pharmaceutical products.

The company imports from abroad, so its future prospects will be tied to the ease of bringing those products into the country.

The company also exports abroad, so it can have a much larger market reach than its size would imply.

The company has experience working as a government supplier, having been awarded several contracts in the last 5 years.

The company works with a well-known bank in the country.

There were no legal filings found against the company.

 

APPENDIX

Person Interviewed

 

Mario Ramirez

Position

 

Finacial Manager

Comments

 

We contacted the company and the operator told us Mr. Ramirez was not available to take our call, and asked us to email him to verify the necessary information.

We did so and are awaiting a reply.

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.65.57

UK Pound

1

Rs.101.13

Euro

1

Rs.71.80

 

INFORMATION DETAILS

 

Analysis Done by :

KAS

 

 

Report Prepared by :

TRU

 

               

RATING EXPLANATIONS

 

RATING

STATUS

PROPOSED CREDIT LINE

 

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

 

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

 

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

 

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

 

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

 

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

 

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

Credit not recommended

 

--

NB

New Business

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.